Jeena Sikho Lifecare Ltd Q3 FY2026 Concall Summary

Key Takeaways

• Strong quarter despite seasonal weakness: Revenue grew well in both services and products, with EBITDA margin holding above 45% even as the company continued investing in expansion. Q3 is normally the weakest quarter for hospitals.
• Product business is scaling fast: The first product crossed INR10 crores in monthly sales, triggering the launch of a second product this month. A pipeline of 15 more products is targeted by December 2026, and an exclusive distribution deal with Entero gives access to 1.25 lakh medical stores.
• Strategy is shifting toward asset-light growth: Management is deliberately reducing low-margin government business and franchises while scaling higher-margin products, health insurance, and OTC channels. The new "Super Specialty Clinic" chain and international centers will start as company-owned.
• Management consistently deflects on numeric guidance: When asked to raise FY26 revenue guidance or provide next-year sales targets, management declined to answer, telling analysts to "do the calculation yourself." Specific data requests on patient recurrence and acquisition details were also deferred.
• What to watch next quarter: Whether the two delayed medical colleges become operational this month as promised, the pace of Entero distribution ramp-up, and any disclosure of Chandan partnership economics.

Product Business Scale-Up

• First product milestone hit: The Pet Yakrit Pleeha Shuddhi Kit crossed INR10 crores in monthly sales, which was management's internal trigger to launch the second product.
• Second product launching now: NutriRoz, a nutritional supplement with 33 herbs targeting children, adults, and the elderly, launches this month as an OTC product available both online and offline.
• Aggressive pipeline target: Management has identified 15 products "which are the need of every human" and targets 16 total products launched by December 31, 2026. Six to eight products are ready in the next three to five months, including a blood purifier, BP pills, and sugar pills. Nine clinical trials are already completed.
• Entero distribution locked in: An exclusive Ayurveda partnership was finalized last week with Entero, which has a 10% share of all medical stores in India. Goods start shipping to Entero in the next 15 days, and the agreement will be uploaded to NSE this week.
• OTC ambition: Management targets INR500 crores in OTC revenue within two financial years, and claims about 40% of product margin goes to the distribution network while still maintaining service-level profit margins.
• Manufacturing backward integration: The company plans to start its own manufacturing this year, either through a tie-up with a ready-made factory or a greenfield setup. Management expects this will increase margins and improve quality control.

Manish Grover: "My target was that when the first product crosses INR10 crores in monthly sales, I will launch the second product."

Occupancy & Bed Expansion Strategy

• Deliberate seasonal management: Management chose not to make 500 additional beds operational in Q3 because it is the weakest quarter for hospitals, and activating them would have increased expenses and reduced profit margins. Instead, they focused on filling already operational beds.
• Occupancy held at 58%: Despite Q3 being weak across the hospital industry, occupancy was maintained at 58%. Management plans to reach 70%-80% occupancy and maintain that level.
• Bed ramp-up coming: From March to September, hospital beds fill up, and management will make additional beds operational this month. Currently, 2,700 to 2,800 beds are under development, with a long-term target of 7,000 to 10,000 beds in the next three to five years.
• Medical colleges delayed deliberately: Two of three medical colleges were not started last quarter because it was a weak period. Management says both will become operational this month.

Channel Mix Shift

• Government business being reduced: Management is deliberately shrinking government business because it carries no margin and payments do not arrive on time. The focus has shifted entirely to private business and health insurance.
• Health insurance driving growth: Health insurance is currently less than 25% of business but grew strongly last quarter. Day care treatments have started getting reimbursed, and patient occupancy did not decrease in the last quarter whereas it routinely does in every hospital.
• Franchises being phased out: The company is slowly reducing franchises over three years and replacing them with own centers. Existing franchises are only clinics contributing very little sales; the main contribution comes from products, hospitals, and day care centers.
• Chandan partnership boosting footfall: Despite Q3 being a weak quarter, footfall increased because of the Chandan diagnostics deal. First testing is free; after the second test, commission goes to the patient's card. All investment, capex, and manpower is Chandan's; Jeena Sikho gives them a percentage of collection. A co-branded card has been created, and 64 centers will become operational in six months with a target of INR5 lakhs per day.

Manish Grover: "When I am doing so well with private business, doing such good work with health insurance companies, I don't think I should increase the government business right now until their portal is fully settled and until the government starts giving payments on time."

New Formats & Geographic Expansion

• Super Specialty Clinic chain: A new chain of "Super Specialty Clinic Hospitals" is being launched in India for mid-section diseases. These will have separate cabins for separate doctors, all with Panchkarma, and will be VVIP. The first 5 to 10 will be company-owned; after proving profitability, management will decide on franchising. Hiring has started, and the plan is to open in every state capital.
• International centers operational: Two international day care centers are now operational in Abu Dhabi, with four more being built in Dubai. Operations have also started in Kazakhstan and Nepal, with planning for the US and other countries ongoing. These centers will act as feeders to fill hospitals in India.
• VVIP room upgrades: 28 rooms in the old Meerut/Muradnagar facility are being upgraded to VVIP-ready. Management has brought in the head of a very large wellness company to open VVIP premium centers.
• Wellness segment emerging: Wellness patients grew from 5% to 15% of the mix this quarter. Management says they are now working on both illness and wellness, not just illness.

Manish Grover: "I want to make it the number 1 company in India, then Asia, and then the world."

Margin & Cost Structure

• EBITDA margin above 45%: Operational efficiency remained strong despite continuous investment in expansion, new centers, and facilities. Management says the 20%-25% EBITDA margin is what should be maintained, and anything higher is "God's grace."
• Product margins match services: Despite roughly 40% of product margin going to the distribution network, this quarter's product sales maintained the same profit margin as from services.
• Low patient acquisition cost: Management claims that while large hospitals spend INR8,000-9,000 just to acquire a patient, Jeena Sikho treats the patient for that amount. Ad spend today is the same as three years ago, while net profit has moved from 6% to 30%, which management attributes to repeats and word-of-mouth.
• Professionalization underway: A COO has been hired, 4-5 corporate people have joined, Forvis Mazars has been appointed as internal auditor, and the company is implementing Oracle after already deploying Salesforce.

Manish Grover: "That is our margin; that is what should be maintained, and if it comes in higher, it's God's grace."

Management's Stance on Disclosure

• Revenue guidance deflected: When asked if FY26 guidance of INR750 crores would be raised, management declined to answer, saying "I don't pay attention to numbers... You do the calculation yourself sir." The company had already done INR586 crores in nine months.
• Next-year sales guidance deflected: When asked for next year's sales guidance, management again told the analyst to look at the last four years' consistent performance and "do the calculation yourself."
• Patient recurrence data unavailable: An analyst asked what percentage of patients are recurring. Management said they do not work on repeats, they teach patients how to live, and while Salesforce has been implemented, such data has not been extracted yet. The analyst was told to email a specific person to extract it.
• Chandan economics deferred: When asked how much profit the Chandan partnership generated this quarter, management declined, saying "we have just started before two months, so the number will come next quarter."
• Historical revenue breakup not provided: When asked for FY24 and FY23 annual revenue breakups, management gave only FY25 numbers and said "we are maintaining the same proportion."

Manish Grover: "Sir, we will put in full effort. You see our consistent performance over the last 4 years, then you do the calculation yourself."

Guidance & Commitments

Key Metrics